Report center
投资建议 入选基药目录产品销售增量明显，建议关注相关重点公司的潜力品种入选新版基药目录情况。关注公司：贵州三力、康恩贝、达仁堂、佐力药业、一品红、太极集团、康缘药业
No subject companies
Ranked by edge type and evidence strength (max 5). Prefer these over scrolling the full lists.
No related reports
← Back to knowledge graph
